Dao Thanh

Researchers are conducting a randomized, double-blind, placebo-controlled Phase 2/3 trial to assess the safety, effectiveness, and antiviral effects of CP-COV03 in adults infected with dengue. The study includes patients diagnosed with dengue via NS1 testing within 72 hours of fever onset in Phase 2, and patients with dengue or dengue-like illnesses such as zika, influenza, or COVID-19 in Phase 3. The trial aims to better understand how CP-COV03 works against dengue infection and its symptoms. Participants will be randomly assigned to receive either CP-COV03 at doses of 450, 900, or 1,350 mg per day, or a placebo, all administered orally for 7 days. An independent board will review interim data from Phase 2 to help select the best dose for Phase 3. The study is designed to compare the effects of the drug with placebo in two parts covering confirmed dengue cases and dengue-like illnesses. During the study, researchers will monitor participants for adverse events and serious adverse events from the first day of treatment through 29 days after. They will also measure viral load on Day 3 and track the time it takes for symptoms to improve up to Day 15. Patients will be assessed regularly for symptoms and side effects to evaluate the treatment’s safety and effectiveness throughout the study period.